1TZG | L:1-106; M:1-106 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A 13-RESIDUE PEPTIDE CONTAINING THE 4E10 EPITOPE ON GP41 |
1U2H | A: | X-RAY STRUCTURE OF THE N-TERMINALLY TRUNCATED HUMAN APEP-1 |
1U6A | L:1-107 | CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV FAB F105 |
1WT5 | A:; B: | THE CRYSTAL STRUCTURE OF A HUMANIZED ANTIBODY FV 528 |
1X9Q | A:14-124; A:153-268 | 4M5.3 ANTI-FLUORESCEIN SINGLE CHAIN ANTIBODY FRAGMENT (SCFV) |
1YA5 | A:1-100; A:101-198; B:1-100; B:101-197 | CRYSTAL STRUCTURE OF THE TITIN DOMAINS Z1Z2 IN COMPLEX WITH TELETHONIN |
1ZA6 | A:1-113; C:1-113; E:1-113; G:1-113 | THE STRUCTURE OF AN ANTITUMOR CH2-DOMAIN-DELETED HUMANIZED ANTIBODY |
1ZLS | L:2-107 | FAB 2G12 + MAN4 |
1ZLU | K:2-107; L:2-107 | FAB 2G12 + MAN5 |
1ZLV | K:2-107; L:2-107 | FAB 2G12 + MAN7 |
1ZLW | K:2-107; L:2-107 | FAB 2G12 + MAN8 |
1ZT4 | C:184-281 | THE CRYSTAL STRUCTURE OF HUMAN CD1D WITH AND WITHOUT ALPHA-GALACTOSYLCERAMIDE |
2A38 | A:1-100; A:101-194; B:1-100; B:101-194; C:1-100; C:101-194 | CRYSTAL STRUCTURE OF THE N-TERMINUS OF TITIN |
2A9M | L:; M: | STRUCTURAL ANALYSIS OF A TIGHT-BINDING FLUORESCEIN-SCFV; APO FORM |
2AJ3 | A:2-107; C:2-107; E:2-107 | CRYSTAL STRUCTURE OF A CROSS-REACTIVE HIV-1 NEUTRALIZING CD4-BINDING SITE ANTIBODY FAB M18 |
2AXH | A:3-115; A:116-244; B:3-115; B:116-244 | CRYSTAL STRUCTURES OF T CELL RECEPTOR BETA CHAINS RELATED TO RHEUMATOID ARTHRITIS |
2AXJ | A:3-115; A:116-244; B:3-115; B:116-244 | CRYSTAL STRUCTURES OF T CELL RECEPTOR BETA CHAINS RELATED TO RHEUMATOID ARTHRITIS |
2BNU | A:2-115 | STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES |
2CDF | A:3-115; A:116-193; B:2-116; B:117-245 | STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE-SPECIFIC T CELL RECEPTORS (TCR 5E) |
2CDG | A:10-115; B:3-117; B:118-246 | STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE-SPECIFIC T CELL RECEPTORS (TCR 5B) |
2CMR | L:1-106A | CRYSTAL STRUCTURE OF THE HIV-1 NEUTRALIZING ANTIBODY D5 FAB BOUND TO THE GP41 INNER-CORE MIMETIC 5-HELIX |
2D3V | A:3-94; A:95-195 | CRYSTAL STRUCTURE OF LEUKOCYTE IG-LIKE RECEPTOR A5 (LILRA5/LIR9/ILT11) |
2D7T | H: | CRYSTAL STRUCTURE OF HUMAN ANTI POLYHYDROXYBUTYRATE ANTIBODY FV |
2D9C | A: | SOLUTION STRUCTURE OF THE FIRST IG-LIKE DOMAIN OF SIGNAL-REGULATORY PROTEIN BETA-1 (SIRP-BETA-1) |
2DL9 | A: | SOLUTION STRUCTURE OF THE IG-LIKE DOMAIN OF HUMAN LEUCINE-RICH REPEAT-CONTAINING PROTEIN 4 |
2DM2 | A: | SOLUTION STRUCTURE OF THE FIRST IG DOMAIN OF HUMAN PALLADIN |
2DM3 | A: | SOLUTION STRUCTURE OF THE SECOND IG DOMAIN OF HUMAN PALLADIN |
2EDF | A: | SOLUTION STRUCTURE OF THE SECOND IG-LIKE DOMAIN(2826-2915) FROM HUMAN OBSCURIN |
2EDJ | A: | SOLUTION STRUCTURE OF THE FIFTH IG-LIKE DOMAIN FROM HUMAN ROUNDABOUT HOMOLOG 2 |
2EDK | A: | SOLUTION STRUCTURE OF THE THIRD IG-LIKE DOMAIN FROM HUMAN MYOSIN-BINDING PROTEIN C, FAST-TYPE |
2EDN | A: | SOLUTION STRUCTURE OF THE FIRST IG-LIKE DOMAIN FROM HUMAN MYOSIN-BINDING PROTEIN C, FAST-TYPE |
2EIZ | B: | CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV MUTANT(HW47Y)-HEN LYSOZYME COMPLEX |
2EKS | B: | CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV-HEN LYSOZYME COMPLEX |
2ENY | A: | SOLUTION STRUCTURE OF THE IG-LIKE DOMAIN (2735-2825) OF HUMAN OBSCURIN |
2EO1 | A: | SOLUTION STRUCTURE OF THE IG DOMAIN OF HUMAN OBSCN PROTEIN |
2EYR | A:1-117; B:3-119 | A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION |
2EYS | A:1-117; B:3-119 | A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION |
2EYT | A:1-117; B:3-119; C:1-117; D:3-119 | A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION |
2F8V | A:2-100; A:101-195; B:1-100; B:101-197; C:4-100; C:101-194; D:2-100; D:101-194 | STRUCTURE OF FULL LENGTH TELETHONIN IN COMPLEX WITH THE N-TERMINUS OF TITIN |
2FJF | A:1-107; C:1-107; E:1-107; G:1-107; J:1-107; L:1-107; M:1-107; O:1-107; Q:1-107; S:1-107; U:1-107; W:1-107 | STRUCTURE OF THE G6 FAB, A PHAGE DERIVED VEGF BINDING FAB |
2FJG | A:1-107; L:1-107 | STRUCTURE OF THE G6 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF |
2FJH | A:1-106; L:1-106 | STRUCTURE OF THE B20-4 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF |
2FL5 | A:1-106; A:107-212; C:1-106; C:107-212; E:1-106; E:107-212; L:1-106; L:107-212 | COFACTOR-CONTAINING ANTIBODIES: CRYSTAL STRUCTURE OF THE ORIGINAL YELLOW ANTIBODY |
2GI7 | A:2-88; A:89-183; B:0-88; B:89-183 | CRYSTAL STRUCTURE OF HUMAN PLATELET GLYCOPROTEIN VI (GPVI) |
2GW5 | A:3-97 | CRYSTAL STRUCTURE OF LIR-2 (ILT4) AT 1.8 : DIFFERENCES FROM LIR-1 (ILT2) IN REGIONS IMPLICATED IN THE BINDING OF THE CYTOMEGALOVIRUS CLASS I MHC HOMOLOG UL18 |
2H32 | A: | CRYSTAL STRUCTURE OF THE PRE-B CELL RECEPTOR |
2H9G | A:1-107; L:1-107 | CRYSTAL STRUCTURE OF PHAGE DERIVED FAB BDF1 WITH HUMAN DEATH RECEPTOR 5 (DR5) |
2HFF | A:2-106A; L:1-106A | CRYSTAL STRUCTURE OF CB2 FAB |
2HFG | L:1-106A | CRYSTAL STRUCTURE OF HBR3 BOUND TO CB3S-FAB |
2IAL | A:1-109; B:2-112; C:1-109; D:2-112 | STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR |
2IAM | C:1-109; D:2-112 | STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR |
2IAN | D:1-109; E:3-112; I:1-109; J:2-112; N:1-109; O:3-112; S:1-109; T:3-112 | STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR |
2J6E | M:1-108 | CRYSTAL STRUCTURE OF AN AUTOIMMUNE COMPLEX BETWEEN A HUMAN IGM RHEUMATOID FACTOR AND IGG1 FC REVEALS A NOVEL FC EPITOPE AND EVIDENCE FOR AFFINITY MATURATION |
2JB5 | L:3-112 | FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-1 |
2JB6 | A:3-112; L:4-112 | FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-2 |
2JJS | A:; B: | STRUCTURE OF HUMAN CD47 IN COMPLEX WITH HUMAN SIGNAL REGULATORY PROTEIN (SIRP) ALPHA |
2JJT | A:; B: | STRUCTURE OF HUMAN CD47 IN COMPLEX WITH HUMAN SIGNAL REGULATORY PROTEIN (SIRP) ALPHA |
2JJU | A:; B: | STRUCTURE OF HUMAN SIGNAL REGULATORY PROTEIN (SIRP) BETA |
2JJV | A:; B: | STRUCTURE OF HUMAN SIGNAL REGULATORY PROTEIN (SIRP) BETA(2) |
2JJW | A: | STRUCTURE OF HUMAN SIGNAL REGULATORY PROTEIN (SIRP) GAMMA |
2KDG | A: | SOLUTION STRUCTURE OF THE 1ST IG DOMAIN OF MYOTILIN |
2KKQ | A: | SOLUTION NMR STRUCTURE OF THE IG-LIKE C2-TYPE 2 DOMAIN OF HUMAN MYOTILIN. NORTHEAST STRUCTURAL GENOMICS TARGET HR3158. |
2NMS | A: | THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE INHIBITOR RECEPTOR EXPRESSED ON MYELOID CELLS IREM-1 |
2NTS | P:3-118 | CRYSTAL STRUCTURE OF SEK-HVB5.1 |
2NW2 | A:1-117; B:1-118; B:119-247 | CRYSTAL STRUCTURE OF ELS4 TCR AT 1.4A |
2NYY | C:1-111 | CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN TYPE A COMPLEXED WITH MONOCLONAL ANTIBODY CR1 |
2OLD | A:1-112; B:1-112 | BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(2)21 CRYSTAL FORM |
2OM5 | A:4-99; A:100-204; A:205-295; A:296-384 | N-TERMINAL FRAGMENT OF HUMAN TAX1 |
2OMB | A:1-112; B:1-112; C:1-112; D:1-112 | BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(1)21 CRYSTAL FORM |
2OMN | A:1-112; B:1-112 | BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P4(3)2(1)2 CRYSTAL FORM |
2OTP | A:3-95; B:3-95 | CRYSTAL STRUCTURE OF IMMUNOGLOBULIN-LIKE TRANSCRIPT 1 (ILT1/LIR7/LILRA2) |
2OZ4 | A:283-366; A:186-282; A:367-450 | STRUCTURAL PLASTICITY IN IGSF DOMAIN 4 OF ICAM-1 MEDIATES CELL SURFACE DIMERIZATION |
2PYF | A:1-115 | CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEALNATIVE DIAGONAL BINDING GEOMETRY UNBOUND TCR CLONE 5-1 |
2Q87 | A:; B:; C: | THE CRYSTAL STRUCTURE OF THE HUMAN IRP60 ECTODOMAIN |
2QQK | L:1-107 | NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB |
2QQL | L:1-106 | NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB |
2QQN | L:1-107 | NEUROPILIN-1 B1 DOMAIN IN COMPLEX WITH A VEGF-BLOCKING FAB |
2R56 | L:1-107; M:1-107 | CRYSTAL STRUCTURE OF A RECOMBINANT IGE FAB FRAGMENT IN COMPLEX WITH BOVINE BETA-LACTOGLOBULIN ALLERGEN |
2UV3 | A:; B: | STRUCTURE OF THE SIGNAL-REGULATORY PROTEIN (SIRP) ALPHA DOMAIN THAT BINDS CD47. |
2V9T | A: | COMPLEX BETWEEN THE SECOND LRR DOMAIN OF SLIT2 AND THE FIRST IG DOMAIN FROM ROBO1 |
2VLM | D:3-112; E:5-115; E:116-244 | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN |
2VXQ | L:1-107 | CRYSTAL STRUCTURE OF THE MAJOR GRASS POLLEN ALLERGEN PHL P 2 IN COMPLEX WITH ITS SPECIFIC IGE-FAB |
2VXS | L:1-108; M:1-108; N:1-108; O:2-108 | STRUCTURE OF IL-17A IN COMPLEX WITH A POTENT, FULLY HUMAN NEUTRALISING ANTIBODY |
2VXV | L:1-107 | CRYSTAL STRUCTURE OF HUMAN IGG ABT-325 FAB FRAGMENT |
2WBJ | A:82-180; C:8-113; E:82-180; G:10-113 | TCR COMPLEX |
2WP3 | T: | CRYSTAL STRUCTURE OF THE TITIN M10-OBSCURIN LIKE 1 IG COMPLEX |
2WQR | A:228-330; A:331-438; A:439-545; B:225-330; B:331-438; B:439-546 | THE HIGH RESOLUTION CRYSTAL STRUCTURE OF IGE FC |
2WUB | L:1-107; Q:1-107 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP |
2WUC | L:1-107 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP AND AC-KQLR-CHLOROMETHYLKETONE |
2WWK | T: | CRYSTAL STRUCTURE OF THE TITIN M10-OBSCURIN LIKE 1 IG F17R MUTANT COMPLEX |
2WWM | D:; T: | CRYSTAL STRUCTURE OF THE TITIN M10-OBSCURIN LIKE 1 IG COMPLEX IN SPACE GROUP P1 |
2XA8 | L:1-111 | CRYSTAL STRUCTURE OF THE FAB DOMAIN OF OMALIZUMAB AT 2.41A |
2XNA | A:2-111; B:3-115; B:116-243 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN HUMAN T CELL RECEPTOR AND STAPHYLOCOCCAL ENTEROTOXIN |
2XQB | L:5-107 | CRYSTAL STRUCTURE OF ANTI-IL-15 ANTIBODY IN COMPLEX WITH HUMAN IL-15 |
2XTJ | D: | THE CRYSTAL STRUCTURE OF PCSK9 IN COMPLEX WITH 1D05 FAB |
2XWT | B:2-107 | CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A BLOCKING TYPE TSHR AUTOANTIBODY |
2XY1 | A:207-300; A:301-398 | CRYSTAL STRUCTURE OF NCAM2 IG3-4 |
2XY2 | A:19-113; A:114-207 | CRYSTAL STRUCTURE OF NCAM2 IG1-2 |
2XZA | L:1-109 | CRYSTAL STRUCTURE OF RECOMBINANT A.17 ANTIBODY FAB FRAGMENT |
2XZC | L:1-109 | CRYSTAL STRUCTURE OF PHOSPHONATE-MODIFIED RECOMBINANT A.17 ANTIBODY FAB FRAGMENT |
2Y9R | T: | CRYSTAL STRUCTURE OF THE M10 DOMAIN OF TITIN |
2YBR | B:; E:; H: | CRYSTAL STRUCTURE OF THE HUMAN DERIVED SINGLE CHAIN ANTIBODY FRAGMENT (SCFV) 9004G IN COMPLEX WITH CN2 TOXIN FROM THE SCORPION CENTRUROIDES NOXIUS HOFFMANN |
2YC1 | B:; E: | CRYSTAL STRUCTURE OF THE HUMAN DERIVED SINGLE CHAIN ANTIBODY FRAGMENT (SCFV) 9004G IN COMPLEX WITH CN2 TOXIN FROM THE SCORPION CENTRUROIDES NOXIUS HOFFMANN |
2YD3 | A:29-123; A:124-228 | CRYSTAL STRUCTURE OF THE N-TERMINAL IG1-2 MODULE OF HUMAN RECEPTOR PROTEIN TYROSINE PHOSPHATASE SIGMA |
2YD5 | A:30-124; A:125-228 | CRYSTAL STRUCTURE OF THE N-TERMINAL IG1-2 MODULE OF HUMAN RECEPTOR PROTEIN TYROSINE PHOSPHATASE LAR |
2YD8 | A:30-124; A:125-227 | CRYSTAL STRUCTURE OF THE N-TERMINAL IG1-2 MODULE OF HUMAN RECEPTOR PROTEIN TYROSINE PHOSPHATASE LAR IN COMPLEX WITH SUCROSE OCTASULPHATE |
2YK1 | L:4-107 | STRUCTURE OF HUMAN ANTI-NICOTINE FAB FRAGMENT IN COMPLEX WITH NICOTINE |
2YKL | L:4-107 | STRUCTURE OF HUMAN ANTI-NICOTINE FAB FRAGMENT IN COMPLEX WITH NICOTINE-11-YL-METHYL-(4-ETHYLAMINO-4-OXO)-BUTANOATE |
2YR3 | A: | SOLUTION STRUCTURE OF THE FOURTH IG-LIKE DOMAIN FROM MYOSIN LIGHT CHAIN KINASE, SMOOTH MUSCLE |
2YSS | B: | CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV MUTANT(HQ39KW47Y)-HEN LYSOZYME COMPLEX |
2YUV | A: | SOLUTION STRUCTURE OF 2ND IMMUNOGLOBULIN DOMAIN OF SLOW TYPE MYOSIN-BINDING PROTEIN C |
2YXM | A: | CRYSTAL STRUCTURE OF I-SET DOMAIN OF HUMAN MYOSIN BINDING PROTEINC |
2ZNW | A:1-106; A:124-236; B:1-106; B:124-236 | CRYSTAL STRUCTURE OF SCFV10 IN COMPLEX WITH HEN EGG LYSOZYME |
2ZNX | A:1-106; A:124-236; B:1-106; B:124-236 | 5-FLUOROTRYPTOPHAN INCORPORATED SCFV10 COMPLEXED TO HEN EGG LYSOZYME |
3AAZ | B:1-112; B:113-229; L:1-112; L:113-228 | CRYSTAL STRUCTURE OF THE HUMANIZED RECOMBINANT FAB FRAGMENT OF A MURINE; ANTIBODY |
3AUV | A:12-117; A:135-253; B:11-117; B:135-252; C:11-117; C:135-252; D:11-118; D:135-253; E:11-117; E:135-252; F:11-117; F:136-252 | PREDICTING AMINO ACID PREFERENCES IN THE COMPLEMENTARITY DETERMINING REGIONS OF AN ANTIBODY-ANTIGEN RECOGNITION INTERFACE |
3B2U | D:1-107; D:108-213; G:1-107; G:108-213; K:1-107; K:108-213; L:1-107; L:108-213; O:1-107; O:108-213; R:1-107; R:108-213; U:1-107; U:108-213; X:1-107; X:108-213 | CRYSTAL STRUCTURE OF ISOLATED DOMAIN III OF THE EXTRACELLULAR REGION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF IMC-11F8 |
3BDY | L:1-107 | DUAL SPECIFIC BH1 FAB IN COMPLEX WITH VEGF |
3BE1 | L:1-107 | DUAL SPECIFIC BH1 FAB IN COMPLEX WITH THE EXTRACELLULAR DOMAIN OF HER2/ERBB-2 |
3BJ9 | 1: | CRYSTAL STRUCTURE OF THE SURROGATE LIGHT CHAIN VARIABLE DOMAIN VPREBJ |
3BN3 | B:1-87; B:88-196 | CRYSTAL STRUCTURE OF ICAM-5 IN COMPLEX WITH AL I DOMAIN |
3BN9 | C:1-107; E:1-107 | CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2 |
3BW9 | A:182-276 | CRYSTAL STRUCTURE OF HLA B*3508 IN COMPLEX WITH A HCMV 12-MER PEPTIDE FROM THE PP65 PROTEIN |
3BWA | A:182-276 | CRYSTAL STRUCTURE OF HLA B*3508 IN COMPLEX WITH A HCMV 8-MER PEPTIDE FROM THE PP65 PROTEIN |
3C08 | L:4-106 | CRYSTAL STRUCTURE THE FAB FRAGMENT OF MATUZUMAB/EMD72000 (FAB72000) |
3D85 | A:1-107 | CRYSTAL STRUCTURE OF IL-23 IN COMPLEX WITH NEUTRALIZING FAB |
3DGG | A:1-110; C:1-110 | CRYSTAL STRUCTURE OF FABOX108 |
3DIF | A:1-107; C:1-107 | CRYSTAL STRUCTURE OF FABOX117 |
3DX9 | B:2-129; D:2-129 | CRYSTAL STRUCTURE OF THE DM1 TCR AT 2.75A |
3EO9 | L:1-107 | CRYSTAL STRUCTURE THE FAB FRAGMENT OF EFALIZUMAB |
3EOA | A:1-107; L:1-107 | CRYSTAL STRUCTURE THE FAB FRAGMENT OF EFALIZUMAB IN COMPLEX WITH LFA-1 I DOMAIN, FORM I |
3EYO | A:1-108; C:1-108 | CRYSTAL STRUCTURE OF ANTI-HUMAN CYTOMEGALOVIRUS ANTIBODY 8F9 |
3FN0 | L:3-107; L:108-211 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB Z13E1 IN COMPLEX WITH A 12-RESIDUE PEPTIDE CONTAINING THE Z13E1 EPITOPE ON GP41 |
3FZU | D:1-107; L:1-107 | IGG1 FAB CHARACTERIZED BY H/D EXCHANGE |
3G04 | A:1-107; A:108-208 | CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A THYROID-STIMULATING AUTOANTIBODY |
3G6A | A:1-108; L:1-108 | CRYSTAL STRUCTURE OF ANTI-IL-13 ANTIBODY CNTO607 |
3G6J | E:1-106; G:1-106 | C3B IN COMPLEX WITH A C3B SPECIFIC FAB |
3GBM | L:3-105; M:3-106A | CRYSTAL STRUCTURE OF FAB CR6261 IN COMPLEX WITH A H5N1 INFLUENZA VIRUS HEMAGGLUTININ. |
3GBN | L:3-106A | CRYSTAL STRUCTURE OF FAB CR6261 IN COMPLEX WITH THE 1918 H1N1 INFLUENZA VIRUS HEMAGGLUTININ |
3GIZ | L:1-107 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ANTI-CD20 ANTIBODY OFATUMUMAB |
3GJE | A:1-110; L:1-110 | RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES |
3GKW | L:1-107 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF NIMOTUZUMAB. AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY |
3GRW | A:150-247; A:248-355; L:1-107 | FGFR3 IN COMPLEX WITH A FAB |
3GSN | A:2-111 | CRYSTAL STRUCTURE OF THE PUBLIC RA14 TCR IN COMPLEX WITH THE HCMV DOMINANT NLV/HLA-A2 EPITOPE |
3H0T | A:1-111 | HEPCIDIN-FAB COMPLEX |
3H3P | H:; I:; L:; M: | CRYSTAL STRUCTURE OF HIV EPITOPE-SCAFFOLD 4E10 FV COMPLEX |
3HC0 | B:1-107; L:1-107 | BHA10 IGG1 WILD-TYPE FAB - ANTIBODY DIRECTED AT HUMAN LTBR |
3HC3 | L:1-107 | BHA10 IGG1 FAB DOUBLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR |
3HC4 | L:1-107 | BHA10 IGG1 FAB QUADRUPLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR |
3HI1 | A:1-107; L:1-107 | STRUCTURE OF HIV-1 GP120 (CORE WITH V3) IN COMPLEX WITH CD4-BINDING-SITE ANTIBODY F105 |
3HI5 | L:1-106 | CRYSTAL STRUCTURE OF FAB FRAGMENT OF AL-57 |
3HI6 | L:2-106; Y:2-106 | CRYSTAL STRUCTURE OF INTERMEDIATE AFFINITY I DOMAIN OF INTEGRIN LFA-1 WITH THE FAB FRAGMENT OF ITS ANTIBODY AL-57 |
3HMW | L:1-106 | CRYSTAL STRUCTURE OF USTEKINUMAB FAB |
3HMX | L:1-106 | CRYSTAL STRUCTURE OF USTEKINUMAB FAB/IL-12 COMPLEX |
3HUJ | E:1-117; F:2-118; G:1-117; H:1-118 | CRYSTAL STRUCTURE OF HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE IN COMPLEX WITH SEMI-INVARIANT NKT CELL RECEPTOR |
3IDX | L:1-107 | CRYSTAL STRUCTURE OF HIV-GP120 CORE IN COMPLEX WITH CD4-BINDING SITE ANTIBODY B13, SPACE GROUP C222 |
3INU | L:1-107; N:1-107 | CRYSTAL STRUCTURE OF AN UNBOUND KZ52 NEUTRALIZING ANTI-EBOLAVIRUS ANTIBODY. |
3JUY | A:1-125; A:143-249; B:1-125; B:143-250; C:1-125; C:143-250; D:1-125; D:143-249; E:1-125; E:143-249; F:1-125; F:143-249 | CRYSTAL STRUCTURE OF A 3B3 VARIANT, A BROADLY NEUTRALIZING HIV-1 SCFV ANTIBODY |
3JWD | L:1-107; O:1-107 | STRUCTURE OF HIV-1 GP120 WITH GP41-INTERACTIVE REGION: LAYERED ARCHITECTURE AND BASIS OF CONFORMATIONAL MOBILITY |
3K2U | L:1-107 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40 |
3KDM | A:3-111; A:112-218; L:3-111; L:112-218 | CRYSTAL STRUCTURE OF HUMAN ANTI-STEROID FAB 5F2 IN COMPLEX WITH TESTOSTERONE |
3KNB | A: | CRYSTAL STRUCTURE OF THE TITIN C-TERMINUS IN COMPLEX WITH OBSCURIN-LIKE 1 |
3KR3 | L:1-108 | CRYSTAL STRUCTURE OF IGF-II ANTIBODY COMPLEX |
3KVQ | A: | CRYSTAL STRUCTURE OF VEGFR2 EXTRACELLULAR DOMAIN D7 |
3KYM | A:1-107; C:1-107; E:1-107; G:1-107; I:1-107; K:1-107; M:1-107; O:1-107 | CRYSTAL STRUCTURE OF LI33 IGG2 DI-FAB |
3L5X | L:1-107 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN IL-13 AND H2L6 FAB |
3L7F | A:1-107; D:1-107; L:1-107 | STRUCTURE OF IL-13 ANTIBODY H2L6, A HUMANIZED VARIANT OF C836 |
3LH2 | H:; I:; J:; K:; L:; M:; N:; O: | CRYSTAL STRUCTURE OF HIV EPITOPE-SCAFFOLD 4E10_1VI7A_S0_002_N 4E10 FV COMPLEX |
3LHP | H:; I:; L:; M: | CRYSTAL STRUCTURE OF HIV EPITOPE-SCAFFOLD 4E10_D0_1ISEA_004_N 4E10 FV COMPLEX |
3LMJ | L:1-112 | STRUCTURE OF HUMAN ANTI HIV 21C FAB |
3LRS | B:3-107; D:3-107; F:3-107; L:3-107 | STRUCTURE OF PG16, AN ANTIBODY WITH BROAD AND POTENT NEUTRALIZATION OF HIV-1 |
3LZF | L:2-107 | CRYSTAL STRUCTURE OF FAB 2D1 IN COMPLEX WITH THE 1918 INFLUENZA VIRUS HEMAGGLUTININ |
3M8O | H:1-118; H:119-221; L:1-112 | HUMAN IGA1 FAB FRAGMENT |
3MA9 | L:2-109; L:110-210 | CRYSTAL STRUCTURE OF GP41 DERIVED PROTEIN COMPLEXED WITH FAB 8066 |
3MAC | L:2-109; L:110-211 | CRYSTAL STRUCTURE OF GP41-DERIVED PROTEIN COMPLEXED WITH FAB 8062 |
3MFF | A:11-121; B:2-115; C:11-121; D:2-115 | 1F1E8HU TCR |
3MFG | B: | CRYSTAL STRUCTURE OF TOXIC SHOCK SYNDROME TOXIN 1 (TSST-1) IN COMPLEX WITH THE HUMAN T CELL RECEPTOR BETA CHAIN VBETA2.1 (EP-8) |
3MLR | L:1-111 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 2557 IN COMPLEX WITH A NY5 V3 PEPTIDE |
3MLS | L:1-111; M:1-111; N:1-111; O:1-111 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 MAB 2557 FAB IN COMPLEX WITH A HIV-1 GP120 V3 MIMOTOPE |
3MLT | A:1-111; D:1-111; G:1-111; L:1-111 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 2557 IN COMPLEX WITH A UG1033 V3 PEPTIDE |
3MLU | L:2-112 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 2557 IN COMPLEX WITH A ZAM18 V3 PEPTIDE |
3MLV | L:2-112; M:1-112 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 2557 IN COMPLEX WITH AN NOF V3 PEPTIDE |
3MLX | L:2-108; M:2-108 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 3074 IN COMPLEX WITH AN MN V3 PEPTIDE |
3MLY | L:1-107; M:1-107 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 3074 IN COMPLEX WITH A UR29 V3 PEPTIDE |
3MLZ | L:1-107 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 3074 IN COMPLEX WITH A VI191 V3 PEPTIDE |
3MUG | A:2-107; C:2-107; E:3-107; G:2-107; I:1-107; K:3-107 | CRYSTAL STRUCTURE OF HUMAN FAB PG16, A BROADLY REACTIVE AND POTENT HIV-1 NEUTRALIZING ANTIBODY |
3MUH | L:2-107 | CRYSTAL STRUCTURE OF PG9 LIGHT CHAIN |
3MXW | L:1-107 | CRYSTAL STRUCTURE SONIC HEDGEHOG BOUND TO THE 5E1 FAB FRAGMENT |
3N9G | L:1-111 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THE HUMAN NEUTRALIZING ANTI-WEST NILE VIRUS MAB CR4354 |
3NA9 | L:1-107 | CRYSTAL STRUCTURE OF FAB15 |
3NAA | L:1-107 | CRYSTAL STRUCTURE OF FAB15 MUT5 |
3NAB | L:1-107 | CRYSTAL STRUCTURE OF FAB15 MUT6 |
3NAC | L:1-107 | CRYSTAL STRUCTURE OF FAB15 MUT7 |
3NCJ | L:1-107 | CRYSTAL STRUCTURE OF FAB15 MUT8 |
3NFP | B:1-106; L:1-106 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THERAPEUTIC ANTIBODY DACLIZUMAB IN COMPLEX WITH IL-2RA (CD25) ECTODOMAIN |
3NFS | L:1-106 | CRYSTAL STRUCTURE THE FAB FRAGMENT OF THERAPEUTIC ANTIBODY DACLIZUMAB |
3NGB | C:1-107; C:108-216; F:3-107; F:108-216; K:1-107; K:108-216; L:3-107; L:108-216 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC01 IN COMPLEX WITH HIV-1 GP120 |
3NH7 | L:2-109; L:110-211; M:2-109; M:110-211; N:2-109; N:110-211; O:2-109; O:110-211 | CRYSTAL STRUCTURE OF THE NEUTRALIZING FAB FRAGMENT ABD1556 BOUND TO THE BMP TYPE I RECEPTOR IA |
3NPS | C:3-106A | CRYSTAL STRUCTURE OF MEMBRANE-TYPE SERINE PROTEASE 1 (MT-SP1) IN COMPLEX WITH THE FAB INHIBITOR S4 |
3NTC | L:1-107; L:108-213 | CRYSTAL STRUCTURE OF KD-247 FAB, AN ANTI-V3 ANTIBODY THAT INHIBITS HIV-1 ENTRY |
3NZH | L:1-107 | CRYSTAL STRUCTURE OF ANTI-EMMPRIN ANTIBODY 5F6 FAB |
3O4L | D:7-111; E:2-117; E:118-246 | GENETIC AND STRUCTURAL BASIS FOR SELECTION OF A UBIQUITOUS T CELL RECEPTOR DEPLOYED IN EPSTEIN-BARR VIRUS |
3O6F | C:1-110; D:1-115; G:1-110; H:1-115 | CRYSTAL STRUCTURE OF A HUMAN AUTOIMMUNE TCR MS2-3C8 BOUND TO MHC CLASS II SELF-LIGAND MBP/HLA-DR4 |
3OAY | K:1-107; L:1-107 | A NON-SELF SUGAR MIMIC OF THE HIV GLYCAN SHIELD SHOWS ENHANCED ANTIGENICITY |
3OAZ | K:1-107; L:1-107 | A NON-SELF SUGAR MIMIC OF THE HIV GLYCAN SHIELD SHOWS ENHANCED ANTIGENICITY |
3OB0 | K:1-107; L:1-107 | A NON-SELF SUGAR MIMIC OF THE HIV GLYCAN SHIELD SHOWS ENHANCED ANTIGENICITY |
3OF6 | A:2-119; B:2-119; C:1-119 | HUMAN PRE-T CELL RECEPTOR CRYSTAL STRUCTURE |
3OJ2 | C:251-359; D:251-359 | CRYSTAL STRUCTURE OF FGF1 COMPLEXED WITH THE ECTODOMAIN OF FGFR2B HARBORING THE A172F PFEIFFER SYNDROME MUTATION |
3OJM | B:251-361 | CRYSTAL STRUCTURE OF FGF1 COMPLEXED WITH THE ECTODOMAIN OF FGFR2B HARBORING P253R APERT MUTATION |
3OJV | C:147-249; C:250-359; D:147-249; D:250-359 | CRYSTAL STRUCTURE OF FGF1 COMPLEXED WITH THE ECTODOMAIN OF FGFR1C EXHIBITING AN ORDERED LIGAND SPECIFICITY-DETERMINING BETAC'-BETAE LOOP |
3OMZ | A:11-116; C:139-250; E:13-116; A:139-250; C:11-116 | CRYSTAL STRUCTURE OF MICA-SPECIFIC HUMAN GAMMA DELTA T CELL RECEPTOR |
3OV6 | A:1000-1093; A:185-280 | CD1C IN COMPLEX WITH MPM (MANNOSYL-BETA1-PHOSPHOMYCOKETIDE) |
3P0V | L:1-107; M:1-107 | ANTI-EGFR/HER3 FAB DL11 ALONE |
3P0Y | L:1-107 | ANTI-EGFR/HER3 FAB DL11 IN COMPLEX WITH DOMAIN III OF EGFR EXTRACELLULAR REGION |
3P2T | A:2-96; A:97-195 | CRYSTAL STRUCTURE OF LEUKOCYTE IG-LIKE RECEPTOR LILRB4 (ILT3/LIR-5/CD85K) |
3PGF | L:1-107 | CRYSTAL STRUCTURE OF MALTOSE BOUND MBP WITH A CONFORMATIONALLY SPECIFIC SYNTHETIC ANTIGEN BINDER (SAB) |
3PL6 | A:82-180; C:2-113 | STRUCTURE OF AUTOIMMUNE TCR HY.1B11 IN COMPLEX WITH HLA-DQ1 AND MBP 85-99 |
3PUC | A: | ATOMIC RESOLUTION STRUCTURE OF TITIN DOMAIN M7 |
3PWP | E:1-117 | THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND HUD PEPTIDE |
3Q1S | L:3-107; L:108-211 | HIV-1 NEUTRALIZING ANTIBODY Z13E1 IN COMPLEX WITH EPITOPE DISPLAY PROTEIN |
3Q5O | A:; B: | CRYSTAL STRUCTURE OF HUMAN TITIN DOMAIN M10 |
3QCT | L:108-213 | CRYSTAL STRUCTURE OF THE HUMANIZED APO LT3015 ANTI-LYSOPHOSPHATIDIC ACID ANTIBODY FAB FRAGMENT |
3QCU | L:108-213; M:108-213 | CRYSTAL STRUCTURE OF THE LT3015 ANTIBODY FAB FRAGMENT IN COMPLEX WITH LYSOPHOSPHATIDIC ACID (14:0) |
3QCV | L:108-213; M:108-213 | CRYSTAL STRUCTURE OF THE LT3015 ANTIBODY FAB FRAGMENT IN COMPLEX WITH LYSOPHOSPHATIDIC ACID (18:2) |
3QDG | E:4-117 | THE COMPLEX BETWEEN TCR DMF5 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND MART-1(26-35)(A27L) PEPTIDE |
3QDJ | E:4-117 | THE COMPLEX BETWEEN TCR DMF5 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND MART-1(27-35) NONAMERIC PEPTIDE |
3QDM | D:2-109; E:2-115 | THE COMPLEX BETWEEN TCR DMF4 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND MART-1(26-35)(A27L) DECAMERIC PEPTIDE |
3QEH | B:1-106; D:1-106; F:1-106; H:2-106 | CRYSTAL STRUCTURE OF HUMAN N12-I15, AN ADCC AND NON-NEUTRALIZING ANTI-HIV-1 ENV ANTIBODY |
3QEQ | D:2-109; E:1-114; E:115-243 | THE COMPLEX BETWEEN TCR DMF4 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND MART-1(27-35) NONAMERIC PEPTIDE |
3QEU | B:4-117; E:3-117 | THE CRYSTAL STRUCTURE OF TCR DMF5 |
3QFJ | E:1-117 | THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE MODIFIED TAX (Y5F) PEPTIDE |
3QH3 | B:1-116; D:1-116 | THE CRYSTAL STRUCTURE OF TCR A6 |
3QHF | L:1-107 | CRYSTAL STRUCTURE OF FAB DEL2D1, A DELETION VARIANT OF ANTI-INFLUENZA ANTIBODY 2D1 |
3QHZ | L:2-107; M:4-107 | CRYSTAL STRUCTURE OF HUMAN ANTI-INFLUENZA FAB 2D1 |
3QIB | C:2-111 | CRYSTAL STRUCTURE OF THE 2B4 TCR IN COMPLEX WITH MCC/I-EK |
3QNX | A:1-112; B:3-118; B:119-221 | ORTHORHOMBIC FORM OF HUMAN IGA1 FAB FRAGMENT, SHARING SAME FV AS IGG |
3QNY | A:2-112; B:3-118; B:119-221; C:1-112; D:4-118; D:119-221 | MONOCLINIC FORM OF HUMAN IGA1 FAB FRAGMENT, SHARING SAME FV AS IGG |
3QO1 | A:1-112 | MONOCLINIC FORM OF IGG1 FAB FRAGMENT (APO FORM) SHARING SAME FV AS IGA |
3QOS | | [entry was replaced by entry 5I1D without any SCOP domain information] |
3QOT | | [entry was replaced by entry 5I18 without any SCOP domain information] |
3QPQ | C:1-107; E:1-107; I:1-107; L:1-107 | CRYSTAL STRUCTURE OF ANTI-TLR3 ANTIBODY C1068 FAB |
3QPX | L:1-106 | CRYSTAL STRUCTURE OF FAB C2507 |
3QQ9 | C:1-111; L:1-111 | CRYSTAL STRUCTURE OF FAB FRAGMENT OF ANTI-HUMAN RSV (RESPIRATORY SYNCYTIAL VIRUS) F PROTEIN MAB 101F |
3QRG | L:1-111 | CRYSTAL STRUCTURE OF ANTIRSVF FAB B21M |
3R1G | L:1-107 | STRUCTURE BASIS OF ALLOSTERIC INHIBITION OF BACE1 BY AN EXOSITE-BINDING ANTIBODY |
3REV | A:3-117 | CRYSTAL STRUCTURE OF HUMAN ALLOREACTIVE TCR NB20 |
3RPI | B:3-96; L:3-96 | CRYSTAL STRUCTURE OF FAB FROM 3BNC60, HIGHLY POTENT ANTI-HIV ANTIBODY |
3S6C | A:1001-1093; A:177-277 | STRUCTURE OF HUMAN CD1E |
3S97 | C:133-237; D:133-237; D:238-329 | PTPRZ CNTN1 COMPLEX |
3SDX | A:184-280; C:184-277; E:1-114; F:2-118; F:119-247; G:1-114; H:1-118; H:119-247 | CRYSTAL STRUCTURE OF HUMAN AUTOREACTIVE-VALPHA24 NKT TCR IN COMPLEX WITH CD1D-BETA-GALACTOSYLCERAMIDE |
3SE8 | L:1-107 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC03 IN COMPLEX WITH HIV-1 GP120 |
3SE9 | L:1-107 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC-PG04 IN COMPLEX WITH HIV-1 GP120 |
3SKJ | L:1-107; M:1-107 | STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF AN AGONISTIC ANTI-HUMAN EPHA2 MONOCLONAL ANTIBODY |
3SKN | A:2-124; B:3-126; C:2-124; D:3-126; E:2-124; F:3-126; G:2-124; H:3-126 | CRYSTAL STRUCTURE OF THE RL42 TCR UNLIGANDED |
3SM5 | | [entry was replaced by entry 5UGY without any SCOP domain information] |
3SOB | L:1-107; L:108-213 | THE STRUCTURE OF THE FIRST YWTD BETA PROPELLER DOMAIN OF LRP6 IN COMPLEX WITH A FAB |
3SQO | L:2-107; L:108-214 | PCSK9 J16 FAB COMPLEX |
3T0V | A: | UNLIGANDED FLUOROGEN ACTIVATING PROTEIN M8VL |
3T0W | A:; B: | FLUOROGEN ACTIVATING PROTEIN M8VL IN COMPLEX WITH DIMETHYLINDOLE RED |
3T0X | A:; B: | FLUOROGEN ACTIVATING PROTEIN M8VLA4(S55P) IN COMPLEX WITH DIMETHYLINDOLE RED |
3T2N | L:1-108; M:1-108 | HUMAN HEPSIN PROTEASE IN COMPLEX WITH THE FAB FRAGMENT OF AN INHIBITORY ANTIBODY |
3TCL | B:1-107; L:1-107 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING ANTIBODY CH04 |
3THM | L:1-111 | CRYSTAL STRUCTURE OF FAS RECEPTOR EXTRACELLULAR DOMAIN IN COMPLEX WITH FAB EP6B_B01 |
3TJE | L:1-111 | CRYSTAL STRUCTURE OF FAS RECEPTOR EXTRACELLULAR DOMAIN IN COMPLEX WITH FAB E09 |
3TNM | B:4-107; L:4-107 | CRYSTAL STRUCTURE OF A32 FAB, AN ADCC MEDIATING ANTI-HIV-1 ANTIBODY |
3TNN | B:4-108; D:4-108; F:4-108; L:4-108 | CRYSTAL STRUCTURE OF N5-I5 FAB, AN ADCC MEDIATING AND NON-NEUTRALIZING CD4I ANTI-HIV- 1 ANTIBODY. |
3TO4 | C:1-117; D:3-121 | STRUCTURE OF MOUSE VALPHA14VBETA2-MOUSECD1D-ALPHA-GALACTOSYLCERAMIDE |
3TV3 | L:3-107 | CRYSTAL STRUCTURE OF BROAD AND POTENT HIV-1 NEUTRALIZING ANTIBODY PGT128 IN COMPLEX WITH MAN9 |
3TWC | L:3-107 | CRYSTAL STRUCTURE OF BROAD AND POTENT HIV-1 NEUTRALIZING ANTIBODY PGT127 IN COMPLEX WITH MAN9 |
3TZV | A:1-114; B:2-118; B:119-246; C:184-278; G:1-114; H:2-118; H:119-246 | CRYSTAL STRUCTURE OF AN INKT TCR IN COMPLEX WITH CD1D-LYSOPHOSPHATIDYLCHOLINE |
3U1S | L:2-107; L:108-213 | CRYSTAL STRUCTURE OF HUMAN FAB PGT145, A BROADLY REACTIVE AND POTENT HIV-1 NEUTRALIZING ANTIBODY |
3U2S | B:2-107; L:2-107 | CRYSTAL STRUCTURE OF PG9 FAB IN COMPLEX WITH V1V2 REGION FROM HIV-1 STRAIN ZM109 |
3U30 | B:1-107; E:1-107 | CRYSTAL STRUCTURE OF A LINEAR-SPECIFIC UBIQUITIN FAB BOUND TO LINEAR UBIQUITIN |
3U46 | B:1-107; L:1-107 | CH04H/CH02L P212121 |
3U4B | L:1-107 | CH04H/CH02L FAB P4 |
3U4E | B:2-107; L:1-107 | CRYSTAL STRUCTURE OF PG9 FAB IN COMPLEX WITH V1V2 REGION FROM HIV-1 STRAIN CAP45 |
3U6R | A:; B:; H:; L: | THREE DIMENSIONAL STRUCTURE OF BROADLY NEUTRALIZING ANTI - HEPATITIS C VIRUS (HCV) GLYCOPROTEIN E2 SINGLE CHAIN FV FRAGMENT 1:7 |
3U7W | L:1-105; L:106-214 | CRYSTAL STRUCTURE OF NIH45-46 FAB |
3U7Y | L:3-101; L:102-210 | STRUCTURE OF NIH45-46 FAB IN COMPLEX WITH GP120 OF 93TH057 HIV |
3UTP | D:2-112; E:1-117; K:2-112; L:1-117 | 1E6 TCR SPECIFIC FOR HLA-A*0201-ALWGPDPAAA |
3UX9 | B:4-111; B:136-254; D:4-111; D:136-255 | STRUCTURAL INSIGHTS INTO A HUMAN ANTI-IFN ANTIBODY EXERTING THERAPEUTIC POTENTIAL FOR SYSTEMIC LUPUS ERYTHEMATOSUS |
3VWJ | A:184-278; C:1-117; D:3-118; D:119-246 | TERNARY CRYSTAL STRUCTURE OF THE HUMAN NKT TCR-CD1D-C20:2 COMPLEX |
3VWK | C:2-117; D:3-118 | TERNARY CRYSTAL STRUCTURE OF THE HUMAN NKT TCR-CD1D-4'DEOXY-ALPHA-GALACTOSYLCERAMIDE COMPLEX |
3VXQ | A:1-113; B:2-114; B:115-243; D:1-113; E:2-114; E:115-243 | H27-14 TCR SPECIFIC FOR HLA-A24-NEF134-10 |
3VXT | A:2-111; B:1-112; B:113-241; C:2-111; D:1-112; D:113-241 | T36-5 TCR SPECIFIC FOR HLA-A24-NEF134-10 |
3W9D | B:1-107; D:1-107 | STRUCTURE OF HUMAN MONOCLONAL ANTIBODY E317 FAB |
3W9E | B:1-107 | STRUCTURE OF HUMAN MONOCLONAL ANTIBODY E317 FAB COMPLEX WITH HSV-2 GD |
3WD5 | L:1-106 | CRYSTAL STRUCTURE OF TNFALPHA IN COMPLEX WITH ADALIMUMAB FAB FRAGMENT |
3WJJ | A:233-341; A:342-444; B:238-341; B:342-443 | CRYSTAL STRUCTURE OF IIB SELECTIVE FC VARIANT, FC(P238D), IN COMPLEX WITH FCGRIIB |
3WJL | A:232-341; A:342-443; B:237-341; B:342-444 | CRYSTAL STRUCTURE OF IIB SELECTIVE FC VARIANT, FC(V12), IN COMPLEX WITH FCGRIIB |
3ZL4 | L:3-110 | ANTIBODY STRUCTURAL ORGANIZATION: ROLE OF KAPPA - LAMBDA CHAIN CONSTANT DOMAIN SWITCH IN CATALYTIC FUNCTIONALITY |
3ZTN | L:1-106 | STRUCTURE OF INFLUENZA A NEUTRALIZING ANTIBODY SELECTED FROM CULTURES OF SINGLE HUMAN PLASMA CELLS IN COMPLEX WITH HUMAN H1 INFLUENZA HAEMAGGLUTININ. |
4ACP | A:238-341; A:342-444; B:237-341; B:342-444 | DEACTIVATION OF HUMAN IGG1 FC BY ENDOGLYCOSIDASE TREATMENT |
4AEN | A:84-180 | HLA-DR1 WITH COVALENTLY LINKED CLIP106-120 IN REVERSED ORIENTATION |
4AH2 | A:84-180 | HLA-DR1 WITH COVALENTLY LINKED CLIP106-120 IN CANONICAL ORIENTATION |
4AIZ | A:; B:; C:; D: | CRYSTALLOGRAPHIC STRUCTURE OF 3MJL2 FROM THE GERMINAL LINE LAMBDA 3 |
4AL8 | L:1-107 | STRUCTURE OF DENGUE VIRUS DIII IN COMPLEX WITH FAB 2H12 |
4BM7 | A:237-341; A:342-443; B:238-341; B:342-445 | CRYSTAL STRUCTURE OF IGG FC F241A MUTANT WITH NATIVE GLYCOSYLATION |
4BSV | A:236-341; A:342-445; B:236-341; B:342-445 | HETERODIMERIC FC ANTIBODY AZYMETRIC VARIANT 1 |
4BSW | A:236-341; A:342-445; B:236-341; B:342-445 | HETERODIMERIC FC ANTIBODY AZYMETRIC VARIANT 2 |
4BYH | A:238-341; A:342-444; B:236-341; B:342-444 | CRYSTAL STRUCTURE OF SIALYLATED IGG FC |
4CMM | A: | STRUCTURE OF HUMAN CD47 IN COMPLEX WITH HUMAN SIGNAL REGULATORY PROTEIN (SIRP) ALPHA V1 |
4D9L | L:1-108; M:1-108; N:1-108; O:1-108 | FAB STRUCTURE OF ANTI-HIV-1 GP120 V2 MAB 697 |
4D9Q | D:1-107; L:1-107 | INHIBITING ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION BY TARGETING THE EXOSITE ON FACTOR D |
4D9R | D:1-107; L:1-107 | INHIBITING ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION BY TARGETING THE EXOSITE ON FACTOR D |
4DEP | B:7-104; B:105-207; B:208-310; E:6-104; E:105-207; E:208-314 | STRUCTURE OF THE IL-1B SIGNALING COMPLEX |
4DKF | L:1-106; M:1-106 | CRYSTAL STRUCTURE OF HUMAN INTERLEUKIN-34 BOUND TO FAB2 |
4DQO | L:1-107 | CRYSTAL STRUCTURE OF PG16 FAB IN COMPLEX WITH V1V2 REGION FROM HIV-1 STRAIN ZM109 |
4DTG | L:1-111 | HEMOSTATIC EFFECT OF A MONOCLONAL ANTIBODY MAB 2021 BLOCKING THE INTERACTION BETWEEN FXA AND TFPI IN A RABBIT HEMOPHILIA MODEL |
4DZB | A:1-110; B:2-117 | MUCOSAL-ASSOCIATED INVARIANT T CELL RECEPTOR, VALPHA7.2JALPHA33-VBETA2 |
4E41 | D:1-110; E:1-110; I:1-110; J:1-110 | STRUCTURAL BASIS FOR THE RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED T CELL RECEPTOR G4 |
4E42 | A:1-110; B:2-110; C:1-110; D:2-110 | STRUCTURAL BASIS FOR THE RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED T CELL RECEPTOR G4 |
4EDW | L:1-107 | NERVE GROWTH FACTOR IN COMPLEX WITH FAB FROM HUMANIZED VERSION OF MOUSE MAB 911 (TANEZUMAB) |
4EN3 | A:8-113; B:2-117 | CRYSTAL STRUCTURE OF A HUMAN VALPHA24(-) NKT TCR IN COMPLEX WITH CD1D/ALPHA-GALACTOSYLCERAMIDE |
4EOW | L:2-111 | CRYSTAL STRUCTURE OF A DISEASE-ASSOCIATED ANTI-HUMAN GM-CSF AUTOANTIBODY MB007 |
4ERS | L:1-106 | A MOLECULAR BASIS FOR NEGATIVE REGULATION OF THE GLUCAGON RECEPTOR |
4EVN | B:3-112; D:3-112; F:3-112; H:3-112; J:3-112; L:3-112; N:3-112; P:3-112 | CRYSTAL STRUCTURE OF FAB CR6261 (SOMATIC HEAVY CHAIN WITH GERMLINE-REVERTED LIGHT CHAIN) |
4EZM | A:335-436; A:437-545; B:336-436; B:437-545; C:336-436; C:437-545; D:335-436; D:437-541; E:335-436; E:437-540; F:335-436; F:437-542 | CRYSTAL STRUCTURE OF THE HUMAN IGE-FC(EPSILON)3-4 BOUND TO ITS B CELL RECEPTOR DERCD23 |
4F57 | L:1-108 | FAB STRUCTURE OF A NEUTRALIZING ANTIBODY L1 FROM AN EARLY SUBTYPE A HIV-1 INFECTED PATIENT |
4F58 | L:1-108; M:1-108; N:1-108; O:1-108 | FAB STRUCTURE OF A NEUTRALIZING ANTIBODY L3 FROM AN EARLY SUBTYPE A HIV-1 INFECTED PATIENT |
4FNL | L:1-106; M:1-106 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY C05 |
4FP8 | L:1-106; M:1-106; N:1-106; O:1-106 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY C05 BOUND TO H3 INFLUENZA HEMAGGLUTININ, HA1 SUBUNIT |
4FQ1 | L:9-108; L:109-209 | CRYSTAL STRUCTURE OF PGT121 FAB |
4FQ2 | L:8-108 | CRYSTAL STRUCTURE OF 10-1074 FAB |
4FQC | L:10-108; L:109-209 | CRYSTAL STRUCTURE OF PGT121 FAB BOUND TO A COMPLEX-TYPE SIALYLATED N-GLYCAN |
4FQH | B:2-107; L:2-107 | CRYSTAL STRUCTURE OF FAB CR9114 |
4FQI | L:2-107 | CRYSTAL STRUCTURE OF FAB CR9114 IN COMPLEX WITH A H5N1 INFLUENZA VIRUS HEMAGGLUTININ |
4FQJ | L:1-107 | INFLUENZA B/FLORIDA/4/2006 HEMAGGLUTININ FAB CR8071 COMPLEX |
4FQX | A:82-181 | CRYSTAL STRUCTURE OF HLA-DM BOUND TO HLA-DR1 |
4FZ8 | L:1-107 | CRYSTAL STRUCTURE OF C11 FAB, AN ADCC MEDIATING ANTI-HIV-1 ANTIBODY. |
4FZE | L:2-107 | CRYSTAL STRUCTURE OF N26_I1 FAB, AN ADCC MEDIATING ANTI-HIV-1 ANTIBODY. |
4G3Y | L:1-107 | CRYSTAL STRUCTURE OF TNF-ALPHA IN COMPLEX WITH INFLIXIMAB FAB FRAGMENT |
4G7V | L:1-107 | CRYSTAL STRUCTURE OF VOLTAGE SENSING DOMAIN OF CI-VSP WITH FRAGMENT ANTIBODY (R217E, 2.5 A) |
4G7Y | L:1-107 | CRYSTAL STRUCTURE OF VOLTAGE SENSING DOMAIN OF CI-VSP WITH FRAGMENT ANTIBODY (R217E, 2.8 A) |
4G8E | A:1-127; B:3-134 | CRYSTAL STRUCTURE OF CLONE18 TCR |
4G8F | A:3-128; B:1-127 | CRYSTAL STRUCTURE OF CLONE42 TCR |
4GRL | C:2-113 | CRYSTAL STRUCTURE OF A AUTOIMMUNE TCR-MHC COMPLEX |
4GRM | B:3-117; D:1-117 | THE CRYSTAL STRUCTURE OF THE HIGH AFFINITY TCR A6 |
4GSD | L:5-108 | H5.3 FAB STRUCTURE |
4GW4 | B:4-96; L:4-96 | CRYSTAL STRUCTURE OF 3BNC60 FAB WITH P61A MUTATION |
4GXV | L:1-107; M:1-107 | CRYSTAL STRUCTURE OF ANTI-INFLUENZA VIRUS ANTIBODY 1F1 |
4H8W | L:3-108 | CRYSTAL STRUCTURE OF NON-NEUTRALIZING AND ADCC-POTENT ANTIBODY N5-I5 IN COMPLEX WITH HIV-1 CLADE A/E GP120 AND SCD4. |
4HAF | A:236-341; A:342-444; B:239-341; B:342-444 | CRYSTAL STRUCTURE OF FC-FRAGMENT OF HUMAN IGG2 ANTIBODY (PRIMITIVE CRYSTAL FORM) |
4HBQ | A:1-90; B:1-90 | CRYSTAL STRUCTURE OF A LOOP DELETED MUTANT OF HUMAN MADCAM-1 D1D2 |
4HC1 | A:9-90; B:9-90 | CRYSTAL STRUCTURE OF A LOOP DELETED MUTANT OF HUMAN MADCAM-1 D1D2 COMPLEXED WITH FAB 10G3 |
4HCR | A:1-90; B:1-90; L:1-111; N:1-111 | CRYSTAL STRUCTURE OF HUMAN MADCAM-1 D1D2 COMPLEXED WITH FAB PF-547659 |
4HD9 | A:1-90 | CRYSTAL STRUCTURE OF NATIVE HUMAN MADCAM-1 D1D2 DOMAIN |
4HF5 | L:3-107 | CRYSTAL STRUCTURE OF FAB 8F8 IN COMPLEX A H2N2 INFLUENZA VIRUS HEMAGGLUTININ |
4HFU | L:1-106 | CRYSTAL STRUCTURE OF FAB 8M2 IN COMPLEX WITH A H2N2 INFLUENZA VIRUS HEMAGGLUTININ |
4HFW | A:2-106; L:1-106 | ANTI ROTAVIRUS ANTIBODY |
4HH9 | A:1-107; C:1-107 | ANTI-HUMAN CYTOMEGALOVIRUS (HCMV) FAB KE5 |
4HIE | A:2-107; A:108-211 | ANTI-STREPTOCOCCUS PNEUMONIAE 23F FAB 023.102 |
4HIH | A:2-107; A:108-211; C:2-107; C:108-211 | ANTI-STREPTOCOCCUS PNEUMONIAE 23F FAB 023.102 WITH BOUND RHAMNOSE. |
4HII | A:2-107; A:108-211; C:2-107; C:108-211 | ANTI-STREPTOCOCCUS PNEUMONIAE 23F FAB 023.102 WITH BOUND RHAMNOSE-GALACTOSE |
4HIJ | A:5-107; A:108-211; C:2-107; C:108-211 | ANTI-STREPTOCOCCUS PNEUMONIAE 23F FAB 023.102 WITH BOUND L-RHAMNOSE-(1-2)-ALPHA-D-GALACTOSE-(3-O)-PHOSPHATE-2-GLYCEROL |
4HJG | A:1-107 | MEDITOPE-ENABLED TRASTUZUMAB |
4HJJ | L:1-113; L:114-228; L:229-327 | STRUCTURE REVEALS FUNCTION OF THE DUAL VARIABLE DOMAIN IMMUNOGLOBULIN (DVD-IG) MOLECULE |
4HK0 | B:1-109; D:1-109 | UCA FAB (UNBOUND) FROM CH65-CH67 LINEAGE |
4HK3 | N:1-109 | I2 FAB (UNBOUND) FROM CH65-CH67 LINEAGE |
4HKX | B:1-109 | INFLUENZA HEMAGGLUTININ IN COMPLEX WITH CH67 FAB |
4HKZ | A:1-107 | TRASTUZUMAB FAB COMPLEXED WITH PROTEIN L AND PROTEIN A FRAGMENTS |
4HQQ | L:1-107 | CRYSTAL STRUCTURE OF RV144-ELICITED ANTIBODY CH58 |
4HWB | L:1-104; L:105-212 | CRYSTAL STRUCTURE OF ECTODOMAIN 3 OF THE IL-13 RECEPTOR ALPHA 1 IN COMPLEX WITH A HUMAN NEUTRALIZING MONOCLONAL ANTIBODY FRAGMENT |
4I2X | A:1-107; C:1-107 | CRYSTAL STRUCTURE OF SIGNAL REGULATORY PROTEIN GAMMA (SIRP-GAMMA) IN COMPLEX WITH FABOX117 |
4I3R | L:1-106 | CRYSTAL STRUCTURE OF THE OUTER DOMAIN OF HIV-1 GP120 IN COMPLEX WITH VRC-PG04 SPACE GROUP P3221 |
4I3S | L:1-107 | CRYSTAL STRUCTURE OF THE OUTER DOMAIN OF HIV-1 GP120 IN COMPLEX WITH VRC-PG04 SPACE GROUP P21 |
4I77 | L:1-107 | LEBRIKIZUMAB FAB BOUND TO IL-13 |
4IIQ | A:2-110; B:2-116 | CRYSTAL STRUCTURE OF A HUMAN MAIT TCR IN COMPLEX WITH BOVINE MR1 |
4IMK | C:3-109; C:110-215; D:3-109; D:110-212 | UNCROSSED FAB BINDING TO HUMAN ANGIOPOIETIN 2 |
4IOI | A:1-107 | MEDITOPE-ENABLED TRASTUZUMAB IN COMPLEX WITH CQFDLSTRRLKC |
4J4P | D:19-130; L:19-130 | THE COMPLEX OF HUMAN IGE-FC WITH TWO BOUND FAB FRAGMENTS |
4J6R | L:1-107 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC23 IN COMPLEX WITH HIV-1 GP120 |
4JAM | B:3-107; L:2-107 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY CH103 |
4JAN | B:2-105; L:2-105 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY CH103 IN COMPLEX WITH HIV-1 GP120 |
4JB9 | L:1-102 | CRYSTAL STRUCTURE OF ANTIBODY VRC06 IN COMPLEX WITH HIV-1 GP120 CORE |
4JFH | E:1-116 | HIGH AFFINITY ALPHA24-BETA17 T CELL RECEPTOR FOR A2 HLA-MELANOMA PEPTIDE COMPLEX |
4JFX | A:1-107; L:1-107 | STRUCTURE OF PHOSPHOTYROSINE (PTYR) SCAFFOLD BOUND TO PTYR PEPTIDE |
4JFY | A:1-107; L:1-107 | APO STRUCTURE OF PHOSPHOTYROSINE (PYAB) SCAFFOLD |
4JFZ | L:1-107 | STRUCTURE OF PHOSPHOSERINE (PSAB) SCAFFOLD BOUND TO PSER PEPTIDE |
4JG0 | L:1-107 | STRUCTURE OF PHOSPHOSERINE/THREONINE (PSTAB) SCAFFOLD BOUND TO PSER PEPTIDE |
4JG1 | L:1-107 | STRUCTURE OF PHOSPHOSERINE/THREONINE (PSTAB) SCAFFOLD BOUND TO PTHR PEPTIDE |
4JHA | L:1-107 | CRYSTAL STRUCTURE OF RSV-NEUTRALIZING HUMAN ANTIBODY D25 |
4JKP | L:3-101; L:102-209 | RESTRICTING HIV-1 PATHWAYS FOR ESCAPE USING RATIONALLY-DESIGNED ANTI-HIV-1 ANTIBODIES |
4JKW | A: | STRUCTURE OF THE EXTRACELLULAR DOMAIN OF BUTYROPHILIN BTN3A1 IN COMPLEX WITH ISOPENTENYL PYROPHOSPHATE (IPP) |
4JM2 | B:1-106 | CRYSTAL STRUCTURE OF PGT 135 FAB IN COMPLEX WITH GP120 CORE PROTEIN FROM HIV-1 STRAIN JR-FL BOUND TO CD4 AND 17B FAB |
4JM4 | L:1-107 | CRYSTAL STRUCTURE OF PGT 135 FAB |
4JPI | B:2-109; L:2-109 | CRYSTAL STRUCTURE OF A PUTATIVE VRC01 GERMLINE PRECURSOR FAB |
4JPK | L:1-109 | CRYSTAL STRUCTURE OF THE GERMLINE-TARGETING HIV-1 GP120 ENGINEERED OUTER DOMAIN EOD-GT6 IN COMPLEX WITH A PUTATIVE VRC01 GERMLINE PRECURSOR FAB |
4JPV | L:1-107 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY 3BNC117 IN COMPLEX WITH HIV-1 GP120 |
4JPW | L:1-107 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY 12A21 IN COMPLEX WITH HIV-1 STRAIN 93TH057 GP120 MUTANT |
4JY4 | A:9-108; A:109-211 | CRYSTAL STRUCTURE OF HUMAN FAB PGT121, A BROADLY REACTIVE AND POTENT HIV-1 NEUTRALIZING ANTIBODY |
4JY5 | L:8-108 | CRYSTAL STRUCTURE OF HUMAN FAB PGT122, A BROADLY REACTIVE AND POTENT HIV-1 NEUTRALIZING ANTIBODY |
4JY6 | A:8-111; A:112-213; C:8-108; C:109-210 | CRYSTAL STRUCTURE OF HUMAN FAB PGT123, A BROADLY REACTIVE AND POTENT HIV-1 NEUTRALIZING ANTIBODY |
4K55 | A: | STRUCTURE OF THE EXTRACELLULAR DOMAIN OF BUTYROPHILIN BTN3A1 IN COMPLEX WITH (E)-4-HYDROXY-3-METHYL-BUT-2-ENYL PYROPHOSPHATE (HMBPP) |
4K7P | X:1-107 | GENERATION AND CHARACTERIZATION OF A UNIQUE REAGENT THAT RECOGNIZES A PANEL OF RECOMBINANT HUMAN MONOCLONAL ANTIBODY THERAPEUTICS IN THE PRESENCE OF ENDOGENOUS HUMAN IGG |
4K94 | L:3-108; L:109-212 | CRYSTAL STRUCTURE OF KIT D4D5 FRAGMENT IN COMPLEX WITH ANTI-KIT ANTIBODY FAB19 |
4KHT | L:2-109; L:110-210 | TRIPLE HELIX BUNDLE OF GP41 COMPLEXED WITH FAB 8066 |
4KHX | L:2-109; L:110-208 | CRYSTAL STRUCTURE OF GP41 HELIX COMPLEXED WITH ANTIBODY 8062 |
4KJY | B:; D: | COMPLEX OF HIGH-AFFINITY SIRP ALPHA VARIANT FD6 WITH CD47 |
4KMT | L:1-107 | CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY 5-51/O12 |
4KQ3 | L:1-106 | CRYSTAL STRUCTURE OF ANTI-IL-17A ANTIBODY CNTO3186 |
4KU1 | A:237-341; A:342-443; B:237-341; B:342-444 | ROLE OF THE HINGE AND C-GAMMA-2/C-GAMMA-3 INTERFACE IN IMMUNOGLOBIN G1 FC DOMAIN MOTIONS: IMPLICATIONS FOR FC ENGINEERING |
4KVN | L:2-106 | CRYSTAL STRUCTURE OF FAB 39.29 IN COMPLEX WITH INFLUENZA HEMAGGLUTININ A/PERTH/16/2009 (H3N2) |
4KY1 | L:1-107 | HUMANIZED HP1/2 FAB |
4L4J | A:237-341; A:342-444; B:239-341; B:342-444 | CRYSTAL STRUCTURE OF FC-FRAGMENT OF HUMAN IGG2-SIGMA ANTIBODY |
4L4T | A:179-269; C:179-269; D:1-110; E:2-116; E:117-244; G:1-110; H:3-116; H:117-244 | STRUCTURE OF HUMAN MAIT TCR IN COMPLEX WITH HUMAN MR1-6-FP |
4L4V | A:179-269; E:117-244; G:1-110; H:3-116; H:117-242; C:179-269; D:1-110; E:2-116 | STRUCTURE OF HUMAN MAIT TCR IN COMPLEX WITH HUMAN MR1-RL-6-ME-7-OH |
4L8S | A:3-110; B:2-115; B:116-243 | CRYSTAL STRUCTURE OF A HUMAN VALPHA7.2/VBETA13.3 MAIT TCR IN COMPLEX WITH BOVINE MR1 |
4LCW | A:179-269; C:179-269; D:1-110; E:2-116; E:117-244; G:1-110; H:3-116; H:117-242 | THE STRUCTURE OF HUMAN MAIT TCR IN COMPLEX WITH MR1-K43A-RL-6-ME-7OH |
4LFH | D:5-120; D:121-206; G:10-125 | CRYSTAL STRUCTURE OF 9C2 TCR |
4LHU | A:184-277; D:5-120; D:121-206; G:10-125 | CRYSTAL STRUCTURE OF 9C2 TCR BOUND TO CD1D |
4LKC | A:2-108 | AN ANTIBODY AGAINST THE C-TERMINAL DOMAIN OF PCSK9 LOWERS LDL CHOLESTEROL LEVELS IN VIVO |
4LL9 | A:2-100; A:101-197; B:2-100; B:101-197; C:2-100; C:101-197 | CRYSTAL STRUCTURE OF D3D4 DOMAIN OF THE LILRB1 MOLECULE |
4LLA | A:4-99; A:100-201; B:4-99; B:100-201; C:4-99; C:100-201 | CRYSTAL STRUCTURE OF D3D4 DOMAIN OF THE LILRB2 MOLECULE |
4LLD | B: | STRUCTURE OF WILD-TYPE IGG1 ANTIBODY HEAVY CHAIN CONSTANT DOMAIN 1 AND LIGHT CHAIN LAMBDA CONSTANT DOMAIN (IGG1 CH1:CLAMBDA) AT 1.19A |
4LLU | B:1-107; B:108-210; D:1-106; D:110-209 | STRUCTURE OF PERTUZUMAB FAB WITH LIGHT CHAIN CLAMBDA AT 2.16A |
4LLV | A:; B:; C:; D:; E:; F:; H:; L: | THE STRUCTURE OF THE UNBOUND FORM OF ANTI-HIV ANTIBODY 4E10 FV |
4LMQ | I:1-107; L:1-107 | DEVELOPMENT AND PRECLINICAL CHARACTERIZATION OF A HUMANIZED ANTIBODY TARGETING CXCL12 |
4LSP | L:1-107 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC-CH31 IN COMPLEX WITH HIV-1 CLADE A/E GP120 93TH057 |
4LSQ | L:1-107 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC-CH31 IN COMPLEX WITH HIV-1 CLADE A/E GP120 93TH057 WITH LOOP D AND LOOP V5 FROM CLADE A STRAIN 3415_V1_C1 |
4LSS | L:3-107; L:108-216 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC01 IN COMPLEX WITH HIV-1 CLADE A STRAIN KER_2018_11 GP120 |
4LST | L:1-107; L:108-216 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC01 IN COMPLEX WITH HIV-1 CLADE C STRAIN ZM176.66 GP120 |
4LSU | L:2-107 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC-PG20 IN COMPLEX WITH HIV-1 CLADE A/E 93TH057 GP120 |
4M1D | L:1-106A; L:107-211; M:2-106A; M:107-209 | CRYSTAL STRUCTURE OF ANTI-HIV-1 FAB 447-52D IN COMPLEX WITH V3 CYCLIC PEPTIDE MN |
4M5Y | L:1-106A; L:107-209; M:1-106A; M:107-209 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING FAB 5J8 |
4M5Z | L:1-106A; L:107-210 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY 5J8 BOUND TO 2009 PANDEMIC INFLUENZA HEMAGGLUTININ, HA1 SUBUNIT |
4M6M | L:1-112 | CRYSTAL STRUCTURE OF ANTI-IL-23 ANTIBODY CNTO1959 AT PH 9.5 |
4M6O | L:1-107 | CRYSTAL STRUCTURE OF ANTI-NGF ANTIBODY CNTO7309 |
4MAY | C:2-113 | CRYSTAL STRUCTURE OF AN IMMUNE COMPLEX |
4MNG | E:2-119; E:147-256; F:2-119; F:147-256 | STRUCTURE OF THE DP10.7 TCR WITH CD1D-SULFATIDE |
4MQ7 | A:184-278 | STRUCTURE OF HUMAN CD1D-SULFATIDE |
4N0F | A:177-267; E:177-267; H:177-267; K:177-267 | HUMAN FCRN COMPLEXED WITH HUMAN SERUM ALBUMIN |
4NDM | A:9-118; B:1-121 | STRUCTURE OF THE AB18.1 TCR |
4NM4 | L:1-107; M:1-107 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY CR8043 |
4NPY | A:1-106A; A:107-208; L:1-106A; L:107-209 | CRYSTAL STRUCTURE OF GERMLINE FAB PGT121, A PUTATIVE PRECURSOR OF THE BROADLY REACTIVE AND POTENT HIV-1 NEUTRALIZING ANTIBODY |
4NQT | A:237-341; A:342-444 | ANTI-PARALLEL FC-HOLE(T366S/L368A/Y407V) HOMODIMER |
4NQU | A:237-341; A:342-444 | ANTI-PARALLEL FC-KNOB (T366W) HOMODIMER |
4NRY | B:1-107; B:108-211; L:1-107; L:108-213 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING ANTIBODY M66 |
4NRZ | B:1-107; L:1-107 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING ANTIBODY M66.6 |
4NZR | L:1-107 | CRYSTAL STRUCTURE OF THE ANTIBODY-BINDING REGION OF PROTEIN M (PROTEIN M TD) IN COMPLEX WITH ANTI-HIV ANTIBODY PGT135 FAB |
4NZT | L:2-107 | CRYSTAL STRUCTURE OF THE ANTIBODY-BINDING REGION OF PROTEIN M (PROTEIN M TD) IN COMPLEX WITH ANTI-INFLEUNZA HEMAGGLUTININ ANTIBODY CR9114 FAB |
4NZU | L:1-107 | CRYSTAL STRUCTURE OF THE PRIMARY MONOCLONAL ANTIBODY 13PL FAB' FROM A MULTIPLE MYELOMA PATIENT |
4OAW | C:1-107 | FAB STRUCTURE OF ANTI-HIV GP120 V2 MAB 2158 |
4OCS | L:3-107 | CRYSTAL STRUCTURE OF HUMAN FAB CAP256-VRC26.10, A POTENT V1V2-DIRECTED HIV-1 NEUTRALIZING ANTIBODY |
4OD1 | L:3-107 | CRYSTAL STRUCTURE OF HUMAN FAB CAP256-VRC26.03, A POTENT V1V2-DIRECTED HIV-1 NEUTRALIZING ANTIBODY |
4OD3 | L:2-107 | CRYSTAL STRUCTURE OF HUMAN FAB CAP256-VRC26.07, A POTENT V1V2-DIRECTED HIV-1 NEUTRALIZING ANTIBODY |
4PS4 | L:1-106 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN IL-13 AND M1295 FAB |